Comment on

• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Polman CH, et al. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. N Engl J Med. 2006. PMID: 16510744 Clinical Trial.
• Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

  Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators. Rudick RA, et al. N Engl J Med. 2006 Mar 2;354(9):911-23. doi: 10.1056/NEJMoa044396. N Engl J Med. 2006. PMID: 16510745 Clinical Trial.
• Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

  Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB. Yousry TA, et al. N Engl J Med. 2006 Mar 2;354(9):924-33. doi: 10.1056/NEJMoa054693. N Engl J Med. 2006. PMID: 16510746 Free PMC article.
• Selective treatment of multiple sclerosis.

  Ropper AH. Ropper AH. N Engl J Med. 2006 Mar 2;354(9):965-7. doi: 10.1056/NEJMe068002. N Engl J Med. 2006. PMID: 16510751 No abstract available.